Prime Medicine, Financial Statements From 2010 to 2024
| PRME Etf | USD 2.97 0.02 0.67% |
Gross Profit -86.7 M | Market Capitalization 389.5 M | Enterprise Value Revenue 319.0859 | Revenue 800 K | Earnings Share (2.06) |
Check Prime Medicine, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Prime Medicine,'s main balance sheet or income statement drivers, such as , as well as many indicators such as . Prime financial statements analysis is a perfect complement when working with Prime Medicine, Valuation or Volatility modules.
Prime |
Prime Medicine, Common ETF Price To Earning Analysis
Prime Medicine,'s Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Prime Medicine, Price To Earning | 14.40 X |
Most of Prime Medicine,'s fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prime Medicine, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Prime Medicine, Common has a Price To Earning of 14.4 times. This is much higher than that of the Biotechnology family and significantly higher than that of the Health Care category. The price to earning for all United States etfs is notably lower than that of the firm.
Prime Medicine, Common Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Prime Medicine,'s current stock value. Our valuation model uses many indicators to compare Prime Medicine, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Prime Medicine, competition to find correlations between indicators driving Prime Medicine,'s intrinsic value. More Info.Prime Medicine, Common is rated below average in price to earning as compared to similar ETFs. It is regarded fourth largest ETF in price to book as compared to similar ETFs fabricating about 0.14 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Prime Medicine, Common is roughly 7.01 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Prime Medicine, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Prime Medicine, Financial Statements
Prime Medicine, stakeholders use historical fundamental indicators, such as Prime Medicine,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although Prime Medicine, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Prime Medicine,'s assets and liabilities are reflected in the revenues and expenses on Prime Medicine,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Prime Medicine, Common. Please read more on our technical analysis and fundamental analysis pages.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.